Spyre Therapeutics, Inc.

NASDAQ (USD): Spyre Therapeutics, Inc. (SYRE)

Last Price

31.93

Today's Change

-1.045 (3.16%)

Day's Change

31.74 - 33.47

Trading Volume

95,481

Profile
SYRE

Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. Cameron Turtle DPHIL, Ph.D. Dr. Cameron Turtle DPHIL, Ph.D.

Full Time Employees:  30 30

IPO Date:  2016-04-07 2016-04-07

CIK:  0001636282 0001636282

ISIN:  US00773J2024 US00773J2024

CUSIP:  00773J202 00773J202

Beta:  2.91 2.91

Last Dividend:  0.00 0.00

Dcf Diff:  17.89 17.89

Dcf:  15.09 15.09

Description

Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Address

221 Crescent Street,
Waltham, MA 02453, US

617 651 5940

http://www.spyre.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment